Drug Profile
DE 104
Alternative Names: DE-104Latest Information Update: 12 Nov 2010
Price :
$50
*
At a glance
- Originator Santen Pharmaceutical; Ube Industries
- Developer Santen Pharmaceutical
- Class Eye disorder therapies
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma; Ocular hypertension
Most Recent Events
- 02 Nov 2010 Discontinued - Phase-II for Glaucoma in Japan (Ophthalmic)
- 02 Nov 2010 Discontinued - Phase-II for Glaucoma in USA (Ophthalmic)
- 02 Nov 2010 Discontinued - Phase-II for Ocular hypertension in Japan (Ophthalmic)